Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs. The company's proprietary technology platform enables the oral delivery of biologics, which are typically administered via injection. Entera Bio's lead product candidate, EB613, is a parathyroid hormone (PTH) analog intended for the treatment of osteoporosis and hypoparathyroidism. The company was founded in 2010 and is headquartered in Jerusalem, Israel.